|
When statins aren't enough: New trial drug points to better management of coronary heart disease
May 09, 2008Penn-led study finds darapladib lowers biomarker for cardiovascular problems
(PHILADELPHIA) - Despite widespread use of cholesterol-lowering drugs, a significant number of cardiac patients continue to suffer heart attacks and stroke. Researchers theorize that high levels of an enzyme found in coronary plaques may be to blame, by making plaques more likely to rupture and block blood flow. The drug darapladib may offer a way to fight that risk, according to new research led by the University of Pennsylvania School of Medicine.
Researchers at the Penn and several other international sites have found that the drug may be a useful adjunct to treatment with statin drugs. The new findings, published in a recent issue of the Journal of the American College of Cardiology, show that the drug safely and effectively lowers the activity of Lp-PLA2, an enzyme associated with inflammation activity and an increased risk for heart attack and stroke.
The trial results pave the way for an important addition to the drugs doctors use to treat heart disease, says the study's lead author, Emile R. Mohler, MD, Director of Vascular Medicine and Associate Professor of Medicine at Penn.
"This is an exciting new area of medical treatment for cardiovascular disease," Mohler says. "It is hoped that this drug will stabilize artery plaque and prevent heart attack and stroke."
The drug was tested at three different dosage levels in about 1,000 patients with coronary heart disease already taking a cholesterol-lowering statin drug. Among patients taking 160 mg of darapladib each day during the 12-week study, blood tests revealed a decrease in two important circulating biomarkers, suggesting a possible reduction in systemic inflammatory burden.
While the drug doesn't necessarily act to shrink the plaques that build inside coronary arteries and choke off blood supply to the heart, Mohler says the research suggests that darapladib may reduce plaque inflammation and therefore lower rates of clot formation and heart attacks among patients with coronary heart disease.
University of Pennsylvania School of Medicine
The trial results pave the way for an important addition to the drugs doctors use to treat heart disease, says the study's lead author, Emile R. Mohler, MD, Director of Vascular Medicine and Associate Professor of Medicine at Penn.
"This is an exciting new area of medical treatment for cardiovascular disease," Mohler says. "It is hoped that this drug will stabilize artery plaque and prevent heart attack and stroke."
The drug was tested at three different dosage levels in about 1,000 patients with coronary heart disease already taking a cholesterol-lowering statin drug. Among patients taking 160 mg of darapladib each day during the 12-week study, blood tests revealed a decrease in two important circulating biomarkers, suggesting a possible reduction in systemic inflammatory burden.
While the drug doesn't necessarily act to shrink the plaques that build inside coronary arteries and choke off blood supply to the heart, Mohler says the research suggests that darapladib may reduce plaque inflammation and therefore lower rates of clot formation and heart attacks among patients with coronary heart disease.
University of Pennsylvania School of Medicine
Coronary Heart Disease News and Current Coronary Heart Disease Events RSSExercise related to lower heart disease risk in overweight women
The risk of heart disease in women associated with being overweight or obese is reduced but not eliminated by higher levels of physical activity, according to a report in the April 28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Thyrotropin levels may be associated with coronary heart disease mortality in women
Women with increasing levels of thyrotropin within the normal range appear to have a higher risk of fatal coronary heart disease, according to a report in the April 28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Genetic variants of USF1 are associated with the increased risk for cardiovascular disease
Cardiovascular diseases (CVD) are major contributors to morbidity and mortality worldwide. Several interacting environmental, biochemical, and genetic risk factors can increase disease susceptibility.
Malfunctioning kidneys may raise risk of sudden death in women
Women whose kidneys are poor at filtering impurities from the blood are at heightened risk of sudden cardiac death, according to a report published in Hypertension: Journal of the American Heart Association.
New Research Shows Benefits of Ultrasound Contrast Agents Outweigh Potential Risk to Heart Patients
ST. LOUIS - A Saint Louis University cardiologist called upon the U.S. Food and Drug Administration (FDA) on Monday to reconsider a strong warning it recently placed on a diagnostic tool, stating that the warning could prevent doctors from detecting life-threatening cardiac events.
Larger belly in mid-life increases risk of dementia
People with larger stomachs in their 40s are more likely to have dementia when they reach their 70s, according to a study published in the March 26, 2008, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Kaiser Permanente study shows that a larger abdomen in midlife increases risk of dementia
People in their 40s with larger stomachs have a higher risk for dementia when they reach their 70s, according to a study published in the March 26, 2008, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Researchers find 1 in 6 women, 1 in 10 men at risk for Alzheimer's disease in their lifetime
Researchers from Boston University School of Medicine (BUSM) have estimated that one in six women are at risk for developing Alzheimer's disease (AD) in their lifetime, while the risk for men is one in ten.
Exercise reduces risk of heart disease in postmenopausal women
Aerobic exercise significantly decreased the chemical imbalances that can lead to heart disease and stroke in postmenopausal women according to a study in the spring issue of the Journal of Women and Aging.
Cancer risk slightly higher for women in discontinued hormone treatment trial
A follow up study of participants in the Women's Health Initiative (WHI) clinical trial led by a University of North Carolina at Chapel Hill researcher has found that women who were taking the combined hormone therapy of estrogen plus progestin may have an increased risk of cancer since the intervention was stopped, compared to participants in the trial's placebo group.
More Coronary Heart Disease News Articles
| © 2008 BrightSurf.com |